Year: 2019
Type: article
Abstract: Lipoprotein(a), Lp(a), is a modified atherogenic low-density lipoprotein particle that contains apolipoprotein(a). Its levels are highly heritable and variable in the population. This consensus statement by HEART UK is based on the evidence that Lp(a) is an independent cardiovascular disease (CVD) risk factor, provides recommendations for its measurement in clinical practice and reviews current and emerging therapeutic strategies to reduce CVD risk. Ten statements summarise the most salient points for practitioners and patients with high Lp(a). HEART UK recommends that Lp(a) is measured in adults as follows: 1) those with a personal or family history of premature atherosclerotic CVD; 2) those with first-degree relatives who have Lp(a) levels >200 nmol/l; 3) patients with familial hypercholesterolemia; 4) patients with calcific aortic valve stenosis and 5) those with borderline (but <15%) 10-year risk of a cardiovascular event. The management of patients with raised Lp(a) levels should include: 1) reducing overall atherosclerotic risk; 2) controlling dyslipidemia with a desirable non-HDL-cholesterol level of <100 mg/dl (2.5 mmol/l) and 3) consideration of lipoprotein apheresis.
Source: Atherosclerosis
Institutions: Imperial College London, Newcastle upon Tyne Hospital, Brighton and Sussex Medical School, University Hospital Southampton NHS Foundation Trust, National Institute for Health and Care Research, NIHR Southampton Biomedical Research Centre, University of Southampton, Swansea University, University Hospital of Wales, University Hospital Llandough, Shrewsbury and Telford Hospital NHS Trust, Queen Mary University of London, William Harvey Research Institute, University of Nottingham, University Hospitals Birmingham NHS Foundation Trust, Lister Hospital, Manchester University NHS Foundation Trust
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,200
OpenAlex ID: W2979293876